{"transactions":[{"id":1082818,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-23T19:36:52.000Z","date":"2025-07-23","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":17500,"derivative":{"exercise_price":1.55,"expiration_date":"2035-07-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-25-098039","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000095017025098039/ownership.xml","form_type":"4"}},{"id":1340518,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-06T16:38:23.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 2, 2024. The shares underlying the option are scheduled to vest in full on December 2, 2025."}],"balance_after":35000,"derivative":{"exercise_price":2.85,"expiration_date":"2034-12-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000950170-24-134160","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000095017024134160/ownership.xml","form_type":"4"}},{"id":1425353,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-08-22T16:06:16.000Z","date":"2024-08-20","kind":"grant","planned":false,"acquired":true,"shares":2725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on August 20, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) August 20, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders."}],"balance_after":2725,"derivative":{"exercise_price":2.4,"expiration_date":"2034-08-19","underlying":"Common Stock","underlying_shares":2725},"source":{"system":"sec-edgar","filing":"0000950170-24-099834","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000095017024099834/ownership.xml","form_type":"4"}},{"id":1543827,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-10T16:15:05.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":2725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 28, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) February 28, 2025 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":2725,"derivative":{"exercise_price":4.72,"expiration_date":"2034-02-27","underlying":"Common Stock","underlying_shares":2725},"source":{"system":"sec-edgar","filing":"0000950170-24-043361","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000095017024043361/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1607151,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-01T16:05:35.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":2725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 28, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) February 28, 2025 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":2725,"derivative":{"exercise_price":4.8,"expiration_date":"2034-02-27","underlying":"Common Stock","underlying_shares":2725},"source":{"system":"sec-edgar","filing":"0000950170-24-023840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000095017024023840/ownership.xml","form_type":"4"}},{"id":2227983,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T17:12:00.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":54500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 15, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders."}],"balance_after":54500,"derivative":{"exercise_price":0.397,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":54500},"source":{"system":"sec-edgar","filing":"0000899243-22-023136","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924322023136/doc4.xml","form_type":"4"}},{"id":2663935,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T19:55:02.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 15, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders."}],"balance_after":96000,"derivative":{"exercise_price":1.29,"expiration_date":"2031-06-14","underlying":"Common Stock","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0000899243-21-024530","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924321024530/doc4.xml","form_type":"4"}},{"id":3105634,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-18T16:30:32.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 17, 2020. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 17, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders"}],"balance_after":12500,"derivative":{"exercise_price":1.15,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-20-017079","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924320017079/doc4.xml","form_type":"4"}},{"id":3107289,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-17T16:31:32.000Z","date":"2020-06-15","kind":"purchase","acquired":true,"shares":5800,"price":1.22,"value":7076.0,"ownership":{"direct":true},"balance_after":5800,"source":{"system":"sec-edgar","filing":"0000899243-20-016859","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924320016859/doc4.xml","form_type":"4"}},{"id":3481515,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-21T16:05:34.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 19, 2019. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 19, 2020 or (ii) the date of the Issuer's 2020 Annual Meeting of Stockholders."}],"balance_after":50000,"derivative":{"exercise_price":0.86,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-19-017791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924319017791/doc4.xml","form_type":"4"}},{"id":3884166,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-25T18:16:45.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 21, 2018. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 21, 2019 or (ii) the date of the Issuer's 2019 Annual Meeting of Stockholders."}],"balance_after":10000,"derivative":{"exercise_price":6.02,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-18-017967","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924318017967/doc4.xml","form_type":"4"}},{"id":4200124,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-09-28T18:20:36.000Z","date":"2017-09-26","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on September 26, 2017. The shares underlying the option are scheduled to vest in equal annual installments over three years from July 25, 2017."}],"balance_after":20000,"derivative":{"exercise_price":12.09,"expiration_date":"2027-09-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-17-022772","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924317022772/doc4.xml","form_type":"4"}},{"id":4264799,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series F Preferred Stock","published_at":"2017-07-05T18:13:21.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":3705882,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":372937},"source":{"system":"sec-edgar","filing":"0000899243-17-017853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924317017853/doc4.xml","form_type":"4"}},{"id":4264798,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series E-3 Preferred Stock","published_at":"2017-07-05T18:13:21.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":2293829,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":230837},"source":{"system":"sec-edgar","filing":"0000899243-17-017853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924317017853/doc4.xml","form_type":"4"}},{"id":4264797,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series E-2 Preferred Stock","published_at":"2017-07-05T18:13:21.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":2644558,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":266132},"source":{"system":"sec-edgar","filing":"0000899243-17-017853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924317017853/doc4.xml","form_type":"4"}},{"id":4264796,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2017-07-05T18:13:21.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":6781770,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":682476},"source":{"system":"sec-edgar","filing":"0000899243-17-017853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924317017853/doc4.xml","form_type":"4"}},{"id":4264795,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2017-07-05T18:13:21.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":4238607,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":426547},"source":{"system":"sec-edgar","filing":"0000899243-17-017853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924317017853/doc4.xml","form_type":"4"}},{"id":4264794,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2017-07-05T18:13:21.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":2967025,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":298583},"source":{"system":"sec-edgar","filing":"0000899243-17-017853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924317017853/doc4.xml","form_type":"4"}},{"id":4264793,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-05T18:13:21.000Z","date":"2017-07-05","kind":"purchase","acquired":true,"shares":266667,"price":15,"value":4000005.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Novartis Bioventures Ltd., a wholly-owned indirect subsidiary of Novartis AG, acquired 266,667 shares of Common Stock in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd."}],"balance_after":2544182,"source":{"system":"sec-edgar","filing":"0000899243-17-017853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924317017853/doc4.xml","form_type":"4"}},{"id":4264792,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":77290,"kind":"person","name":"Ambros Reinhard J.","position":1,"cik":"0001709690","reported_name":"Ambros Reinhard J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-05T18:13:21.000Z","date":"2017-07-05","kind":"exercise","acquired":true,"shares":2277515,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd."}],"balance_after":2277515,"source":{"system":"sec-edgar","filing":"0000899243-17-017853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709690/000089924317017853/doc4.xml","form_type":"4"}}]}